A medicine outside the benzodiazepine class can still alter respiratory effects when combined with an opioid.
What the supplied research shows
An FDA laboratory study used a rat model previously able to detect respiratory worsening with diazepam and oxycodone. Researchers then evaluated several nonbenzodiazepine psychotropic drugs. Certain combinations, including oxycodone with paroxetine or quetiapine, increased arterial carbon dioxide. Much of the observed effect was consistent with increased oxycodone exposure, while the paroxetine combination also suggested an additional mechanism.
What it cannot establish
These were animal experiments with selected exposures and a physiological endpoint. They cannot rank every alternative in humans, establish a human fatal threshold or prove that a particular prescription combination caused an individual event. A rise in arterial carbon dioxide is also not interchangeable with every measure of respiratory compromise.
Forensic interpretation and case review
For a forensic assessment, evaluate both changes in drug concentration and changes in response at a given concentration. Avoid assuming that a substitute is free of interaction merely because it is not a benzodiazepine. The study supports a mechanistic question about the whole regimen; patient records and human evidence are needed to assess its importance in an actual event. It does not establish that all sedating alternatives carry equal risk.
Source and related reading
Source: supplied full-text paper, PMC8604244. Research findings are paraphrased; the case-review discussion is an interpretation of that evidence.
Related: A Small Ketamine Cohort’s Null Benzodiazepine Comparison Does Not Establish No Intubation Risk.
Leave a Reply